On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Another IDH Inhibitor Option for Acute Myeloid Leukemia?

The IDH1 inhibitor olutasidenib, as a single agent and in combination with azacitidine, demonstrated “favorable safety and clinical activity” in patients with IDH1-mutated acute...

Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment

After frontline treatment with corticosteroids fails to elicit a response in patients with chronic immune thrombocytopenia (cITP), the choice between rituximab or thrombopoietin receptor...

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...

Registry Analysis Finds Off-Label Rituximab Improves Outcomes in Patients With iTTP

For patients with de novo immune thrombocytopenic purpura (iTTP), adding rituximab to corticosteroids appears to delay, but not prevent, relapse, according to results from...

Are Clinical Trials Exclusion Criteria for Patients With AML Too Strict?

In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients with acute myeloid leukemia (AML) do not...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve CLL

Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...

Early-Phase Trial Suggests CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma

CC-93269, a bispecific antibody that targets B-cell maturation antigen (BCMA) and CD3 T cells, had a “manageable” safety profile in patients with heavily pretreated...

Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young Women

In a case-based discussion as part of this year’s Education Program, Andra James, MD, MPH, and Margaret Ragni, MD, MPH, will answer challenging questions...

ASH-a-Palooza Redux

The 2018 ASH Annual Meeting in San Diego marked the debut of ASH-a-Palooza, the reimagined Trainee Day. This new educational experience offers a relaxed,...

DOACs: From Clinical Trials to Real-World Clinical Encounters

In the last decade, five direct oral anticoagulants (DOACs) have made their way to the clinic, but clinicians may encounter challenging patient scenarios for...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.